DEF: Akari Seeks Shareholder Approval for Warrant Exercises

Akari Therapeutics, Plc is seeking shareholder approval for the exercisability of warrants issued in recent offerings and a note exchange to comply with Nasdaq listing rules.

Summary

• Akari Therapeutics, Plc is holding a General Meeting of Shareholders on March 2, 2026, to seek approval for the exercisability of various warrants and the issuance of underlying American Depositary Shares (ADSs) and ordinary shares.
• The approval is required to comply with Nasdaq Listing Rules 5635(c) and 5635(d), which govern equity compensation and issuances of 20% or more of voting power below the Nasdaq Minimum Price.
• The warrants include Series G Warrants (10,043,774 ADSs), Placement Agent Warrants (504,300 ADSs) from a Registered Direct Offering and concurrent private placement.
• Also included are Pre-Funded Warrants (2,563,713 ADSs) and Series G Warrants (2,563,713 ADSs) from a Private Placement Offering.
• Additionally, Pre-Funded Warrants (9,502,703 ADSs) and Note Exchange Warrants (9,502,703 ADSs) from a note exchange require approval.
• If shareholder approval is obtained and all cash-exercisable warrants are fully exercised, the Company could receive approximately $8.9 million in gross proceeds.
• The Board of Directors unanimously recommends that shareholders vote FOR all five proposals.
• Failure to obtain approval would prevent the exercise of these warrants and require the Company to incur additional costs by holding subsequent special meetings.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While it highlights significant potential dilution, the primary purpose is to secure shareholder approval for past capital-raising activities and enable future cash proceeds from warrant exercises, which is crucial for funding operations and maintaining Nasdaq compliance.

Positives

• Shareholder approval would enable the Company to potentially receive approximately $8.9 million in gross proceeds from the cash exercise of Series G, Note Exchange, and Placement Agent Warrants.
• Obtaining approval ensures compliance with Nasdaq Listing Rules, avoiding potential delisting issues or penalties.

Negatives

• Approval of the warrant exercise proposals will result in significant dilution for existing shareholders, with the total ordinary shares outstanding increasing from 91,567,009,533 to a projected 159,898,691,533 ordinary shares upon full exercise.
• The sale of these newly issued shares into the public market could materially and adversely affect the market price of the Company's ADSs.

Risks

• Failure to approve the Warrant Exercise Proposals means the Pre-Funded Warrants, Series G Warrants, Note Exchange Warrants, and Placement Agent Warrants cannot be exercised, preventing the Company from realizing potential capital.
• If shareholder approval is not obtained, the Company will be required to hold one or more additional special meetings, incurring substantial additional costs and expenses that could materially and adversely impact its ability to fund operations.
• Existing shareholders will suffer dilution in their ownership interests if the Warrant Exercise Proposals are approved and the underlying shares are issued.
• The potential sale of a large number of shares underlying the warrants into the public market could materially and adversely affect the market price of the Company's ADSs.

Future Outlook

The filing primarily focuses on a procedural vote for warrant exercisability and does not provide specific forward-looking statements or guidance regarding the Company's operational or financial performance beyond the potential capital raise from warrant exercises.

Management Comments

• Abizer Gaslightwala, President and Chief Executive Officer, stated: 'Thank you for your ongoing support of Akari Therapeutics, Plc.'
• The Board of Directors unanimously recommends that shareholders vote FOR each of the Resolutions, believing them to be in the best interests of the Company and its shareholders as a whole and likely to promote the success of the Company.

Industry Context

StockSavvy.ai notes that seeking shareholder approval for warrant exercisability and underlying share issuance is a standard compliance procedure for publicly traded companies, particularly those listed on Nasdaq, when certain thresholds of equity issuance or discounted equity compensation are met. This ensures transparency and adherence to exchange rules, which is crucial for maintaining listing status and investor confidence.

Corporate Governance

Related Party Transactions

• Certain directors and officers of the Company participated in the Private Placement Offering, receiving unregistered Pre-Funded Warrants and accompanying Series G Warrants.

Stakeholder Impact

• Shareholders: Face significant potential dilution of their ownership interests if the warrants are approved and fully exercised, but also benefit from the Company's ability to raise capital and maintain Nasdaq compliance.
• Company: Gains potential access to approximately $8.9 million in capital from warrant exercises, crucial for funding operations, and ensures compliance with Nasdaq listing requirements.
• Warrant Holders: Their warrants become exercisable upon shareholder approval, allowing them to convert into ADSs and potentially realize value.

Next Steps

• The General Meeting of Shareholders will be held on March 2, 2026, to vote on the warrant exercise proposals.
• If shareholder approval is not obtained, the Company will be required to call additional special meetings every 40 days thereafter until approval is secured or the warrants are no longer outstanding.
• The Company has agreed to file a registration statement registering for resale the ADSs issuable upon exercise of the Warrants and Placement Agent Warrants within 30 days of the closing of the offerings.
• Voting results will be announced by filing a current report on Form 8-K with the SEC within four business days following the Meeting.

Key Dates

Recommendation

This filing is primarily procedural, seeking shareholder approval for warrant exercisability to comply with Nasdaq rules and enable potential future capital. While the potential for $8.9 million in capital is positive, the significant dilution (projected 75% increase in ordinary shares) presents a notable downside. A seasoned investor would likely 'hold' as the immediate impact is balanced between capital infusion and dilution, with the outcome of the vote being largely expected for compliance.

Keywords

Akari Therapeutics, AKTX, SEC filing, DEF 14A, proxy statement, shareholder meeting, warrants, registered direct offering, private placement, note exchange, Nasdaq compliance, dilution, capital raise